Business UpdateMay 27, 2026, 08:57 AM
Traws Pharma Announces Antiviral Program for Hantavirus & Ebola
AI Summary
Traws Pharma, Inc. announced the advancement of a novel proprietary broad-spectrum combination antiviral agent targeting ongoing Hantavirus and Ebola Virus disease outbreaks, with potential utility against Lassa. The therapy utilizes a unique "dual-strike" mechanism to hijack host cell pathways for viral eradication, with both components previously evaluated safely in human studies. The company is concurrently scaling up manufacturing and engaging with the US CDC, Nigerian NAFDAC, and the African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and global access.
Key Highlights
- Traws Pharma announced a novel broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks.
- The investigational combination agent utilizes a unique "dual-strike" mechanism of action.
- The mechanism involves host nucleotide depletion and forced lethal incorporation by viral RdRp.
- Both components of the combination have been safely evaluated in human studies as single agents.
- Company is advancing non-clinical development and evaluating the combination in BSL-3 and BSL-4 animal models.
- Traws Pharma is scaling up manufacturing for immediate supply and potential stockpiling.
- Interactions are planned with the US CDC and ongoing with NAFDAC and AMA for fast-track development and access.
Price Impact
More from TRAW